The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...
Symptoms such as headaches or diarrhea can cause men to seek a doctor’s help more than emotional symptoms ... However, with a timely diagnosis and adequate treatment, they can also treat their ...